Corbus Pharmaceuticals Holdings Inc
(NASDAQ : CRBP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.00%205.101.2%$477.70m
GILDGilead Sciences, Inc.
0.91%75.510.9%$401.46m
BIIBBiogen Inc.
1.22%345.411.3%$352.23m
CELGCelgene Corporation
-0.66%87.721.2%$341.18m
ILMNIllumina, Inc.
0.52%358.163.5%$248.76m
REGNRegeneron Pharmaceuticals, Inc.
0.78%390.282.6%$232.51m
VRTXVertex Pharmaceuticals Incorporated
-0.24%180.081.9%$168.98m
EXASExact Sciences Corporation
1.72%76.2825.3%$162.68m
SRPTSarepta Therapeutics, Inc.
-3.43%147.5916.4%$129.44m
AAgilent Technologies, Inc.
-0.58%70.721.5%$124.93m
VKTXViking Therapeutics, Inc.
-4.06%18.200.9%$115.92m
ALXNAlexion Pharmaceuticals, Inc.
-2.10%121.992.0%$114.40m
NKTRNektar Therapeutics
0.96%59.005.6%$106.74m
BMRNBioMarin Pharmaceutical Inc.
-2.55%97.844.4%$97.41m
ALNYAlnylam Pharmaceuticals, Inc
-0.67%94.579.7%$93.14m

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in December 2013 and is headquartered in Norwood, MA.